MCID: HYP263
MIFTS: 45

Hypersomnia

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Hypersomnia

MalaCards integrated aliases for Hypersomnia:

Name: Hypersomnia 50 69

Classifications:



External Ids:

UMLS 69 C0917799

Summaries for Hypersomnia

NINDS : 50 Hypersomnia is characterized by recurrent episodes of excessive daytime sleepiness or prolonged nighttime sleep. Different from feeling tired due to lack of or interrupted sleep at night, persons with hypersomnia are compelled to nap repeatedly during the day, often at inappropriate times such as at work, during a meal, or in conversation. These daytime naps usually provide no relief from symptoms. Patients often have difficulty waking from a long sleep, and may feel disoriented. Other symptoms may include anxiety, increased irritation, decreased energy, restlessness, slow thinking, slow speech, loss of appetite, hallucinations, and memory difficulty. Some patients lose the ability to function in family, social, occupational, or other settings. Hypersomnia may be caused by another sleep disorder (such as narcolepsy or sleep apnea), dysfunction of the autonomic nervous system, or drug or alcohol abuse. In some cases it results from a physical problem, such as a tumor, head trauma, or injury to the central nervous system. Certain medications, or medicine withdrawal, may also cause hypersomnia. Medical conditions including multiple sclerosis, depression, encephalitis, epilepsy, or obesity may contribute to the disorder. Some people appear to have a genetic predisposition to hypersomnia; in others, there is no known cause. Typically, hypersomnia is first recognized in adolescence or young adulthood.

MalaCards based summary : Hypersomnia is related to idiopathic hypersomnia and recurrent hypersomnia, and has symptoms including disruption of 24 hour sleep wake cycle, unspecified, hypersomnia with sleep apnea, unspecified and insomnia with sleep apnea, unspecified. An important gene associated with Hypersomnia is HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1), and among its related pathways/superpathways are Neuroscience and CTLA4 Signaling. The drugs Modafinil and Armodafinil have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and heart, and related phenotypes are behavior/neurological and nervous system

Wikipedia : 72 Hypersomnia, or hypersomnolence, is a neurological disorder of excessive time spent sleeping or... more...

Related Diseases for Hypersomnia

Diseases in the Hypersomnia family:

Recurrent Hypersomnia

Diseases related to Hypersomnia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 103)
# Related Disease Score Top Affiliating Genes
1 idiopathic hypersomnia 34.7 HCRT HLA-DQB1
2 recurrent hypersomnia 34.2 HCRT HLA-DQB1
3 acute disseminated encephalomyelitis 30.4 HCRT HLA-DQB1 HLA-DRB1
4 whipple disease 30.0 HLA-DQB1 HLA-DRB1
5 narcolepsy 29.7 CHKB CPT1B HCRT HCRTR1 HLA-DQB1 HLA-DRB1
6 body mass index quantitative trait locus 11 29.0 CARTPT CPT1B GH1 HCRT PMCH
7 idiopathic hypersomnia without long sleep time 12.1
8 idiopathic hypersomnia with long sleep time 12.0
9 kleine-levin hibernation syndrome 11.5
10 dystonia, dopa-responsive, due to sepiapterin reductase deficiency 11.2
11 myotonic dystrophy 2 10.9
12 atypical depressive disorder 10.9
13 limbic encephalitis with lgi1 antibodies 10.6 HLA-DQB1 HLA-DRB1
14 metal allergy 10.5 HLA-DQB1 HLA-DRB1
15 focal epithelial hyperplasia 10.5 HLA-DQB1 HLA-DRB1
16 beryllium disease 10.5 HLA-DQB1 HLA-DRB1
17 lichen planopilaris 10.5 HLA-DQB1 HLA-DRB1
18 type ii mixed cryoglobulinemia 10.5 HLA-DQB1 HLA-DRB1
19 idiopathic inflammatory myopathy 10.5 HLA-DQB1 HLA-DRB1
20 recurrent respiratory papillomatosis 10.5 HLA-DQB1 HLA-DRB1
21 chronic beryllium disease 10.5 HLA-DQB1 HLA-DRB1
22 autoimmune pancreatitis 10.5 HLA-DQB1 HLA-DRB1
23 pityriasis rosea 10.4 HLA-DQB1 HLA-DRB1
24 muscular dystrophy, congenital, megaconial type 10.4 CHKB PRKN
25 lichen sclerosus 10.4 HLA-DQB1 HLA-DRB1
26 rohhad 10.4 HCRT HCRTR1
27 autoimmune hepatitis 10.4 CYP2D6 HLA-DQB1 HLA-DRB1
28 pediatric multiple sclerosis 10.3 HLA-DQB1 HLA-DRB1
29 osteonecrosis of the jaw 10.3 HLA-DQB1 HLA-DRB1
30 sleep apnea 10.3
31 microscopic colitis 10.1 HLA-DQB1 HLA-DRB1
32 myotonic dystrophy 10.0
33 sleep disorder 10.0
34 central nervous system disease 10.0 CYP2D6 HCRT PRKN
35 traumatic brain injury 10.0
36 major depressive disorder 10.0
37 bipolar disorder 10.0
38 brain injury 10.0
39 parkinson disease, late-onset 9.9 CYP2D6 HCRT PRKN SPR
40 mood disorder 9.9
41 prader-willi syndrome 9.9
42 neuronitis 9.9
43 apnea, obstructive sleep 9.9
44 encephalitis 9.9
45 cerebritis 9.9
46 encephalopathy 9.9
47 body mass index quantitative trait locus 9 9.8
48 epilepsy 9.8
49 myoclonus 9.8
50 insulinoma 9.8

Graphical network of the top 20 diseases related to Hypersomnia:



Diseases related to Hypersomnia

Symptoms & Phenotypes for Hypersomnia

UMLS symptoms related to Hypersomnia:


disruption of 24 hour sleep wake cycle, unspecified, hypersomnia with sleep apnea, unspecified, insomnia with sleep apnea, unspecified, [d]sleep disturbances (& [hypersomnia] or [insomnia]), sleeplessness, excessive daytime somnolence, snoring, sleep disturbances

MGI Mouse Phenotypes related to Hypersomnia:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.65 CARTPT CHKB HCRT HCRTR1 HLA-DQB1 PMCH
2 nervous system MP:0003631 9.32 BCL11A CHKB HCRT HCRTR1 HLA-DQB1 PMCH

Drugs & Therapeutics for Hypersomnia

Drugs for Hypersomnia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 79)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 68693-11-8 4236
2
Armodafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 112111-43-0
3
Dopamine Approved Phase 4,Phase 2,Phase 1 51-61-6, 62-31-7 681
4
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
5
Citalopram Approved Phase 4 59729-33-8 2771
6 Central Nervous System Stimulants Phase 4,Phase 3,Phase 2,Phase 1
7 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3,Phase 2,Phase 1
8 Wakefulness-Promoting Agents Phase 4,Phase 3,Phase 2,Phase 1
9 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
10
Serotonin Phase 4,Phase 2 50-67-9 5202
11 Serotonin Agents Phase 4,Phase 2
12 Serotonin Uptake Inhibitors Phase 4
13 Muscarinic Antagonists Phase 4
14 Cholinergic Agents Phase 4
15 Cholinergic Antagonists Phase 4
16 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1
17 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Phase 1
18 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
19 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2
20 Parasympatholytics Phase 4
21 Dopamine Agents Phase 4,Phase 2,Phase 1
22 Dopamine Uptake Inhibitors Phase 4,Phase 2,Phase 1
23 Antidepressive Agents Phase 4,Phase 2
24 Antidepressive Agents, Second-Generation Phase 4
25 Psychotropic Drugs Phase 4,Phase 2
26 Autonomic Agents Phase 4,Phase 2,Phase 1
27 Antiparkinson Agents Phase 4,Phase 2
28 Anesthetics Phase 4
29
Morphine Approved, Investigational Phase 3 57-27-2 5288826
30
Histamine Approved, Investigational Phase 3,Phase 2 51-45-6, 75614-87-8 774
31
Caffeine Approved, Nutraceutical Phase 2, Phase 3 58-08-2 2519
32
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 2, Phase 3 53-43-0 9860744
33 Analgesics Phase 3
34 Central Nervous System Depressants Phase 3,Phase 2
35 Narcotics Phase 3
36 Analgesics, Opioid Phase 3
37
Histamine Phosphate Phase 3,Phase 2 51-74-1 65513
38 Adjuvants, Immunologic Phase 2, Phase 3
39 Histamine H3 Antagonists Phase 3
40 Phosphodiesterase Inhibitors Phase 2, Phase 3
41 Purinergic P1 Receptor Antagonists Phase 2, Phase 3
42 DHEA (Dehydroepiandrosterone) Nutraceutical Phase 2, Phase 3
43
Levodopa Approved Phase 2 59-92-7 6047
44
Lisuride Approved, Investigational Phase 2 18016-80-3 28864
45
Amphetamine Approved, Illicit, Investigational Phase 2,Phase 1 300-62-9 3007 5826
46
Riluzole Approved, Investigational Phase 2 1744-22-5 5070
47
Minocycline Approved, Investigational Phase 2 10118-90-8 5281021
48
Clarithromycin Approved Phase 2 81103-11-9 84029
49
Flumazenil Approved Phase 1, Phase 2 78755-81-4 3373
50
Menthol Approved Phase 2 2216-51-5 16666

Interventional clinical trials:

(show top 50) (show all 83)

# Name Status NCT ID Phase Drugs
1 Efficacy and Tolerability of Armodafinil in Adults With Excessive Sleepiness Associated With Shift Work Disorder Completed NCT01080807 Phase 4 Armodafinil;Matching Placebo
2 Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression Completed NCT00518986 Phase 4 armodafinil;placebo
3 Study to Evaluate Armodafinil Treatment in Improving Prefrontal Cortical Activation and Working Memory Performance Completed NCT00711516 Phase 4 Armodafinil;Placebo
4 Provigil in Conjunction With SSRIs for the Treatment of Mild or Moderate Depression With Attendant Symptoms of Sleepiness and Fatigue. Completed NCT00208715 Phase 4 Provigil
5 Neuroimaging Study of Bupropion Treatment in Patients With Major Depressive Disorder Completed NCT01541475 Phase 4 Bupropion, Escitalopram;Escitalopram
6 An Eight Week, Double-Blind Efficacy Study of Armodafinil Augmentation to Alleviate Fibromyalgia Fatigue Completed NCT00678691 Phase 4 armodafinil;placebo
7 Palatal Implants in Combination With Continuous Positive Airway Pressure to Treat Obstructive Sleep Apnea Terminated NCT00730041 Phase 4
8 Palliative Morphine With or Without Concurrent Modafinil Unknown status NCT01766323 Phase 3 Modafinil;Placebo
9 Study of the Effect of Armodafinil Treatment in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder Completed NCT00758498 Phase 3 armodafinil;armodafinil;placebo
10 Safety/Efficacy Study With Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Chronic SWSD Completed NCT00080288 Phase 3 Armodafinil 150 mg/day;Placebo
11 Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy Completed NCT00107796 Phase 3 Modafinil
12 PROVIGIL® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome Completed NCT00107848 Phase 3 Modafinil
13 Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome Completed NCT00107809 Phase 3 Modafinil
14 "Six-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA" Completed NCT02348619 Phase 3 JZP-110
15 "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA" Completed NCT02348606 Phase 3 JZP-110
16 Safety and Efficacy Study of Armodafinil (CEP-10953) in the Treatment of Excessive Sleepiness Associated With Narcolepsy Completed NCT00078377 Phase 3 Armodafinil;Armodafinil;Placebo
17 "Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy" Completed NCT02348593 Phase 3 JZP-110
18 Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea (OSA/H) Syndrome Completed NCT00079677 Phase 3 Armodafinil 150 mg/day;Placebo
19 Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome(OSAHS) Completed NCT00078325 Phase 3 Armodafinil 250 mg/day;Armodafinil 150 mg/day;Placebo
20 Assess the Safety and Effectiveness of PROVIGIL Treatment in Children and Adolescents With Excessive Sleepiness Completed NCT00214968 Phase 3 Modafinil
21 Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness Completed NCT00228553 Phase 3 Armodafinil 100 to 250 mg/day
22 "A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA" Completed NCT02348632 Phase 3 JZP-110
23 Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome Completed NCT00228566 Phase 3 Armodafinil
24 Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder Completed NCT00078312 Phase 3 CEP-10953 (Armodafinil)
25 Caffeine for Excessive Daytime Somnolence in Parkinson's Disease Completed NCT00459420 Phase 2, Phase 3 Caffeine 100-200 mg BID;placebo
26 Efficacy and Safety of DHEA for Myotonic Dystrophy Completed NCT00167609 Phase 2, Phase 3 dehydroepiandrosterone 100 and 400 mg
27 Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL Completed NCT00236080 Phase 3 PROVIGIL 200 mg;Armodafinil 250 mg;Armodafinil 200 mg;Armodafinil 150 mg;Placebo
28 Obstructive Sleep Apnea (OSA), Sleepiness, and Activity in Diabetes Management Completed NCT00801892 Phase 3
29 Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy. Completed NCT01638403 Phase 3 BF2.649;Vigil;palcebo
30 Study to Evaluate the Safety, Tolerability, and Efficacy of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury Terminated NCT00983437 Phase 3 Armodafinil
31 Study to Evaluate the Efficacy and Safety of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury Terminated NCT00893789 Phase 3 Armodafinil;Armodafinil;Armodafinil
32 Clarithromycin for the Treatment of Hypersomnia Completed NCT01146600 Phase 2 Clarithromycin followed by placebo;Placebo then Clarithromycin
33 Flumazenil for the Treatment of Primary Hypersomnia Completed NCT01183312 Phase 1, Phase 2 Flumazenil
34 VSF-173 Study in Healthy Adult Volunteers for Treatment of Induced Excessive Sleepiness Completed NCT00467441 Phase 2 VSF-173
35 Pilot Study of Melatonin and Epilepsy Completed NCT00965575 Phase 2 Melatonin
36 A Phase II Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Esophageal Cancer Completed NCT01746043 Phase 2 Armodafinil;Minocycline
37 Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories Completed NCT00247572 Phase 2 NRP104
38 Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse Completed NCT00248092 Phase 1, Phase 2 NRP104
39 Chloral Hydrate to Perform Auditory Brainstem Response (ABR) Completed NCT00949780 Phase 2 Chloral Hydrate
40 Riluzole to Treat Major Depression Completed NCT00026052 Phase 2 riluzole
41 Lisuride Patch to Treat Parkinson's Disease Completed NCT00089622 Phase 2 Intravenous Levodopa;Lisuride Transdermal System
42 Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in Narcolepsy Recruiting NCT02806908 Phase 2 JZP-110;Placebo
43 Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in OSA Recruiting NCT02806895 Phase 2 JZP-110;Placebo
44 A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness Recruiting NCT03037203 Phase 2 JZP-110
45 A Study of Safety and Efficacy of BTD-001 in Treatment of Patients With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2 Active, not recruiting NCT02512588 Phase 2 BTD-001;Placebo
46 Pilot Study of Betahistine Dihydrochloride in the Treatment of Major Depression With Atypical Features Terminated NCT00585585 Phase 2 betahistine dihydrochloride
47 Riluzole to Treat Depression in Bipolar Disorder Terminated NCT00054704 Phase 2 Riluzole;Placebo
48 Double-Blind Placebo-Controlled Trial of Riluzole in Pediatric Bipolar Disorder Terminated NCT00805493 Phase 2 Riluzole
49 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Armodafinil in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy Completed NCT01624480 Phase 1 Armodafinil
50 Effect of Armodafinil on Simulated Driving Completed NCT02468856 Phase 1 armodafinil;Placebo (for armodafinil)

Search NIH Clinical Center for Hypersomnia

Genetic Tests for Hypersomnia

Anatomical Context for Hypersomnia

MalaCards organs/tissues related to Hypersomnia:

38
Brain, Testes, Heart, Hypothalamus, Eye, Pituitary, Thalamus

Publications for Hypersomnia

Articles related to Hypersomnia:

(show top 50) (show all 370)
# Title Authors Year
1
Prevalence, risk factors, and response to treatment for hypersomnia of central origin in survivors of childhood brain tumors. ( 29116485 )
2018
2
Insomnia and hypersomnia in major depressive episode: Prevalence, sociodemographic characteristics and psychiatric comorbidity in a population-based study. ( 28972930 )
2018
3
Alternative diagnostic criteria for idiopathic hypersomnia: A 32-hour protocol. ( 29323727 )
2018
4
Update on treatment for idiopathic hypersomnia. ( 29250981 )
2018
5
Hypersomnia and cognitive impairment in a patient with bipolar disorder - a case report. ( 28866718 )
2017
6
A Case of Recurrent Hypersomnia With Autonomic Dysfunction. ( 28633719 )
2017
7
Neurobiological Basis of Hypersomnia. ( 28778226 )
2017
8
Hypersomnia: Evaluation, Treatment, and Social and Economic Aspects. ( 28159097 )
2017
9
Case Report of a Patient With Idiopathic Hypersomnia and a Family History of Malignant Hyperthermia Undergoing General Anesthesia: An Overview of the Anesthetic Considerations. ( 28328583 )
2017
10
Hypersomnia hiding a bipolar disorder. ( 28687972 )
2017
11
Hypersomnia: an overlooked, but not overestimated, sleep disturbance in bipolar disorder. ( 28235881 )
2017
12
Narcolepsy and hypersomnia in Norwegian children and young adults following the influenza A(H1N1) 2009 pandemic. ( 28302408 )
2017
13
Depression and Hypersomnia: A Complex Association. ( 28778237 )
2017
14
Usefulness of brain SPECT imaging in the study of recurrent hypersomnia: Kleine-Levin syndrome. ( 28869046 )
2017
15
[18F]Fludeoxyglucose-Positron Emission Tomography Evidence for Cerebral Hypermetabolism in the Awake State in Narcolepsy and Idiopathic Hypersomnia. ( 28775709 )
2017
16
Efficacy, Safety, and Tolerability of Armodafinil Therapy for Hypersomnia Associated with Dementia with Lewy Bodies: A Pilot Study. ( 28448998 )
2017
17
Narcolepsy and Other Central Hypersomnias. ( 28777172 )
2017
18
Recurrent Hypersomnia and Autonomic Dysregulation in Posttraumatic Stress Disorder. ( 29117891 )
2017
19
Altered Regional Cerebral Blood Flow in Idiopathic Hypersomnia. ( 28958044 )
2017
20
Val158Met polymorphism in the COMT gene is associated with hypersomnia and mental health-related quality of life in a Colombian sample. ( 28235603 )
2017
21
Idiopathic Hypersomnia. ( 28778232 )
2017
22
Life-time history of insomnia and hypersomnia symptoms as correlates of alcohol, cocaine and heroin use and relapse among adults seeking substance use treatment in the United States from 1991 to 1994. ( 28127809 )
2017
23
Narcolepsy type 1 and hypersomnia associated with a psychiatric disorder show different slow wave activity dynamics. ( 28691719 )
2017
24
Brain MRI findings in patients with idiopathic hypersomnia. ( 28376374 )
2017
25
Test-Retest Reliability of Two Consecutive Mean Sleep Latency Tests in Patients with Hypersomnia. ( 29249902 )
2017
26
Treatment of narcolepsy and other organic hypersomnias in children. ( 28735675 )
2017
27
Hypersomnia in Neurodegenerative Diseases. ( 28778241 )
2017
28
Hypersomnolence, Hypersomnia, and Mood Disorders. ( 28243864 )
2017
29
Diffusion tensor imaging tractography and MRI perfusion in post traumatic brain injury hypersomnia. ( 28522105 )
2017
30
A case of hypersomnia due to bilateral thalamic stroke. ( 29026583 )
2017
31
Evaluation of polygenic risks for narcolepsy and essential hypersomnia. ( 27305985 )
2016
32
Post-stroke hypersomnia. ( 26763039 )
2016
33
Urine Toxicology in Adults Evaluated for a Central Hypersomnia and How the Results Modify the Physician's Diagnosis. ( 27568897 )
2016
34
Disorders of Excessive Daytime Sleepiness Including Narcolepsy and Idiopathic Hypersomnia. ( 27542882 )
2016
35
Behavioral Sleep Medicine Services for Hypersomnia Disorders: A Survey Study. ( 26788889 )
2016
36
Recovery of Hypersomnia Concurrent With Recovery of an Injured Ascending Reticular Activating System in a Stroke Patient: A Case Report. ( 26765455 )
2016
37
French consensus. Idiopathic hypersomnia: Investigations and follow-up. ( 27838089 )
2016
38
Diurnal and nocturnal cardiovascular variability and heart rate arousal response in idiopathic hypersomnia. ( 27810179 )
2016
39
Distribution of HLA-DQB1 in Czech Patients with Central Hypersomnias. ( 28083611 )
2016
40
[Posterior reversible encephalopathy syndrome of the midbrain and hypothalamus - a case report of uremic encephalopathy presenting with hypersomnia]. ( 26640128 )
2016
41
Idiopathic Hypersomnia and Hypersomnolence Disorder: A Systematic Review of the Literature. ( 26895727 )
2016
42
Benefits and risk of sodium oxybate in idiopathic hypersomnia versus narcolepsy type 1: a chart review. ( 26847972 )
2016
43
Hypersomnia as the first presentation in a patient with insulinoma: A case report and review of the literature. ( 27699047 )
2016
44
Injury of the Ascending Reticular Activating System in Patients With Fatigue and Hypersomnia Following Mild Traumatic Brain Injury: Two Case Reports. ( 26871783 )
2016
45
The effects of Transcranial Direct Current Stimulation (tDCS) on Idiopathic Hypersomnia: a pilot study. ( 27548094 )
2016
46
Migraine with brainstem aura presenting as recurrent hypersomnia (Kleine-Levin syndrome). ( 27343267 )
2016
47
Menstruation-Related Hypersomnia Treated with Hormonal Contraception: Case Report and Review of Literature. ( 26932284 )
2016
48
Narcolepsy with and without cataplexy, idiopathic hypersomnia with and without long sleep time: a cluster analysis. ( 25576137 )
2015
49
Neuromyelitis optica spectrum disorder presenting with repeated hypersomnia due to involvement of the hypothalamus and hypothalamus-amygdala linkage. ( 25680985 )
2015
50
Central Disorders of Hypersomnolence: Focus on the Narcolepsies and Idiopathic Hypersomnia. ( 26149554 )
2015

Variations for Hypersomnia

Expression for Hypersomnia

Search GEO for disease gene expression data for Hypersomnia.

Pathways for Hypersomnia

Pathways related to Hypersomnia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.99 CARTPT HCRT PRKN SCN2A
2 10.98 HLA-DQB1 HLA-DRB1 PTPA
3
Show member pathways
10.76 HLA-DQB1 HLA-DRB1 TRA

GO Terms for Hypersomnia

Cellular components related to Hypersomnia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MHC class II protein complex GO:0042613 8.62 HLA-DQB1 HLA-DRB1

Biological processes related to Hypersomnia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.67 CARTPT HCRT HCRTR1 PMCH
2 regulation of neurotransmitter secretion GO:0046928 9.43 HCRT PRKN
3 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.4 HLA-DQB1 HLA-DRB1
4 feeding behavior GO:0007631 9.33 HCRT HCRTR1 PMCH
5 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.32 HLA-DQB1 HLA-DRB1
6 positive regulation of transmission of nerve impulse GO:0051971 9.26 CARTPT HCRT
7 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 8.96 HLA-DQB1 HLA-DRB1
8 neuropeptide signaling pathway GO:0007218 8.92 CARTPT HCRT HCRTR1 PMCH

Molecular functions related to Hypersomnia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MHC class II receptor activity GO:0032395 8.62 HLA-DQB1 HLA-DRB1

Sources for Hypersomnia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....